Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186847 | 0.89 | MAPT (0.70) | TP53MAPTRAB9AL3MBTL1KMT2A | |
| SCHEMBL2186582 | 0.82 | THRB (0.52) | TP53MAPTRAB9AKMT2ATHRB | |
| SCHEMBL12240646 | 0.81 | THRB (0.52) | TP53MAPTRAB9AL3MBTL1KMT2A | |
| SCHEMBL2547296 | 0.80 | MAPT (0.69) | TP53MAPTKMT2ATHRB | |
| SCHEMBL2188136 | 0.80 | THRB (0.51) | TP53MAPTRAB9AL3MBTL1KMT2A | |
| SCHEMBL2173213 | 0.79 | THRB (0.50) | TP53MAPTRAB9AL3MBTL1KMT2A | |
| SCHEMBL2188832 | 0.78 | SHMT2 (0.48) | TP53MAPTRAB9AL3MBTL1KMT2A | |
| SCHEMBL2171642 | 0.78 | MAPT (0.67) | TP53MAPTRAB9AKMT2ATHRB | |
| SCHEMBL2173312 | 0.76 | MAPT (0.61) | TP53MAPTRAB9AKMT2ATHRB | |
| SCHEMBL2546279 | 0.73 | MAPT (0.55) | TP53MAPTKMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | TP53 4565/4885MAPT 2044/4885RAB9A 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.